Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
epilepsy
Biotech
Praxis ends year on high with $100M biobucks UCB deal
It’s been a tough year of layoffs and pipeline culls for Praxis, but the biotech is ending 2022 on a high courtesy of a collaboration with UCB.
James Waldron
Dec 14, 2022 5:29am
Neurocrine's $45M bet goes 0 for 2 with rare epilepsy flop
Dec 7, 2022 7:20am
Kriya buys Redpin to chart gene therapy course in neurology
Nov 16, 2022 11:51am
Biohaven fuels up for post-Pfizer future with $302M
Nov 9, 2022 9:55am
New gene therapy for epilepsy hits seizures where they start
Nov 4, 2022 11:05am
Biohaven veers toward Kv7 platform following Pfizer sale
Oct 4, 2022 11:48am
